Company Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States.
The company’s lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.
The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007.
Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. As of February 3, 2026, Applied Therapeutics, Inc. operates as a subsidiary of Cycle Group Holdings Limited.
| Country | United States |
| Founded | 2016 |
| IPO Date | May 14, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Les Funtleyder |
Contact Details
Address: 545 Fifth Avenue, Suite 1400 New York, New York 10017 United States | |
| Phone | 212 220 9226 |
| Website | appliedtherapeutics.com |
Stock Details
| Ticker Symbol | APLT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 1697532 |
| CUSIP Number | 03828A101 |
| ISIN Number | US03828A1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Les D. Funtleyder | Interm Chief Executive Officer, Chief Financial Officer, Principal Financial Officer and Director |
| Corwin Dale Hooks | Chief Commercial Officer |
| Constantine Chinoporos | Chief Operating Officer and Chief Business Officer |
| Catherine Thorpe | Interim Chief Accounting Officer |
| Reena Thomas Colacot | Head of Quality |
| Dr. Todd F. Baumgartner M.D., M.P.H. | Chief Regulatory Officer |
| Dr. Evan Prescott Bailey M.D. | Chief Medical Officer |
| Dottie Caplan | Executive Vice President of Patient Advocacy and Government Affairs. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 3, 2026 | POS AM | Post-Effective amendments for registration statement |
| Feb 3, 2026 | POS AM | Post-Effective amendments for registration statement |
| Feb 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 3, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 3, 2026 | 25-NSE | Filing |
| Feb 3, 2026 | 8-K | Current Report |
| Feb 3, 2026 | SC 14D9/A | Filing |
| Feb 3, 2026 | SC TO-T/A | Filing |